Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16648400 | 0.90 | ALOX5 (0.49) | ALOX5HMGCR | |
| SCHEMBL5204151 | 0.85 | ALOX5 (0.43) | ALOX5ALOX15MAPTHMGCRIGF1R | |
| SCHEMBL2412893 | 0.85 | LTA4H (0.47) | PPARGALOX5HMGCR | |
| SCHEMBL5206395 | 0.85 | HMGCR (0.50) | AKR1B1PPARGALOX5ALOX15LMNA | |
| SCHEMBL2410166 | 0.84 | PPARG (0.48) | PPARGALOX5MEN1LMNAMAPT | |
| SCHEMBL8637743 | 0.84 | LTA4H (0.56) | PPARGALOX5ALOX15MEN1USP2 | |
| SCHEMBL5208689 | 0.81 | ALOX5 (0.47) | PPARGALOX5THRATHRB | |
| SCHEMBL8635275 | 0.81 | PPARG (0.43) | PPARGALOX5KMT2AHMGCRPPARA | |
| SCHEMBL29810184 | 0.81 | HIF1A (0.63) | AKR1B1ALOX5ALOX15MEN1SLC22A1 | |
| SCHEMBL630770 | 0.81 | HIF1A (0.63) | AKR1B1ALOX5ALOX15MEN1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102584754-B | There is the fused aromatic compounds of anti-diabetic activity | SCHERING CORPORATION (US) | 2016-02-03 | — | — | CN | disclosed |
| EP-1861382-B1 | FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| CN-102584754-A | Fused aromatic compounds having anti-diabetic activity | MERCK SHARP & DOHME | 2012-07-18 | — | — | CN | disclosed |
| US-7834036-B2 | Fused-aromatic compounds having anti-diabetic activity | MERCK SHARP & DOHME CORP (US) | 2010-11-16 | — | — | US | disclosed |
| US-7807692-B2 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807692-B2 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807692-B2 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| US-6200998-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS; ANTICHOLESTEROL, ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. | 2001-03-13 | — | — | US | disclosed |
| CN-1282325-A | Arylthiazolidinedione derivatives | MERCK & CO INC (US) | 2001-01-31 | — | — | CN | disclosed |
| WO-2000078312-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| US-6160000-A | Antidiabetic agents based on aryl and heteroarylacetic acids | MERCK & CO., INC. (US) | 2000-12-12 | — | — | US | disclosed |
| EP-1040102-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6090839-A | REDUCING TRIGLYCERIDE CONCENTRATION | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-6008237-A | POTENT AGONISTS OF PEROXIDSOME PROLIFERATOR ACTIVATED RECEPTOR; FOR CONTROLLING OR PREVENTING OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO., INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0948327-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999032465-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998027974-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | PPARD, PPARA, PPARG | AKR1B1 1646/4885PPARG 3/4885ALOX5 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.